FDA Requests Survival Evidence Before Tovecimig Biologics Filing

Company Compass Therapeutics Event Type Regulatory Feedback Modality Bispecific Antibody Asset Tovecimig Target DLL4 / VEGF-A Disease Area Biliary Tract Cancer Summary Compass disclosed that FDA recommended a trial demonstrating overall survival benefit before a biologics license application for tovecimig in previously treated advanced biliary…